1 domain / 2 areas / 1 specialization
Stifel
Data updated
Stifel is a U.S.-based diversified wealth management and investment banking firm with a corporate headquarters in St. Louis, Missouri. It serves individuals, institutions, and corporations through brokerage, research, investment banking, and related financial services.
In the psychedelic ecosystem, Stifel is mainly relevant as a healthcare and biopharma capital-markets participant rather than a dedicated psychedelic specialist. Its public materials show active coverage of life sciences and biopharma, including venture banking and capital-raising activity in the sector, which makes it a potential advisor or financing counterparty for psychedelic drug developers as they move through public and late-stage markets.
Investor Context
Institutional InvestorsInvestment Context
This stakeholder is listed as an Institutional Investor within Institutional Investors. Its public geography context is global. Public stage signals include Growth / Late Stage, Public Markets, and Multi-Stage. Public focus areas include Drug Development.
Stifel is a long-established public financial services firm with a broad institutional platform rather than a narrowly themed venture fund. Public-facing materials show an emphasis on healthcare, life sciences, and capital raising across private and public markets, including investment banking work for biopharma companies and venture banking efforts in life sciences. That positioning makes Stifel relevant to psychedelic companies mainly as a financing, underwriting, or advisory firm rather than as a dedicated psychedelic investor.
Investor Type
Institutional Investor
Geographic Scope
Global
Psychedelic Focus
No Public Psychedelic Focus
Engagement
Active
Investment Stage Focus
Investment Focus Areas
Quick Facts
- Founded
- 1890
- HQ
- St. Louis, Missouri; One Financial Plaza, 501 North Broadway, United States
- Website
- Visit